Le Lézard
Classified in: Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Fortive Schedules Third Quarter 2023 Earnings Conference Call


Fortive Corporation ("Fortive") (NYSE: FTV) today announced that it will webcast its earnings conference call for the third quarter 2023 on Wednesday, October 25, 2023 beginning at 12:00 p.m. ET and lasting approximately 1 hour.

The call and an accompanying slide presentation will be webcast on the "Investors" section of Fortive's website, www.fortive.com, under "Events/Presentations." A replay of the webcast will be available at the same location shortly after the conclusion of the presentation.

You can access the conference call by dialing 888-440-6928 within the U.S. or 646-960-0328 outside the U.S. a few minutes before 12:00 p.m. ET and notifying the operator that you are dialing in for Fortive's earnings conference call (access code 6922572).

A digital recording of the conference call will be available two hours after the conclusion of the call until Wednesday, November 8, 2023. You can access the conference call replay on the "Investors" section of Fortive's website, www.fortive.com, under "Events/Presentations," or by dialing 800-770-2030 within the U.S. or 647-362-9199 outside the U.S. (access code 6922572).

Fortive's earnings press release, the webcast slides and other related presentation materials will be posted to the "Investors" section of Fortive's website under "Quarterly Results".

Fortive is now in its "quiet period". This quiet period will be in place until fiscal third quarter 2023 earnings are released on October 25, 2023. During this time, Fortive will not be interacting with the investment community.

ABOUT FORTIVE

Fortive is a provider of essential technologies for connected workflow solutions across a range of attractive end-markets. Fortive's strategic segments?Intelligent Operating Solutions, Precision Technologies, and Advanced Healthcare Solutions?include well-known brands with leading positions in their markets. The company's businesses design, develop, service, manufacture, and market professional and engineered products, software, and services, building upon leading brand names, innovative technologies, and significant market positions. Fortive is headquartered in Everett, Washington and employs a team of more than 18,000 research and development, manufacturing, sales, distribution, service and administrative employees in more than 50 countries around the world. With a culture rooted in continuous improvement, the core of our company's operating model is the Fortive Business System. For more information please visit: www.fortive.com.


These press releases may also interest you

at 00:00
XSOOH has always been at the forefront of hair care innovation, striving to deliver cutting-edge  products  that enhance the way customers achieve their desired looks. In a world where time is precious, XSOOH  proudly announces the launch of the...

3 jui 2024
In a landmark event signaling its ambitious foray into the biopharmaceutical sector, LOTTE BIOLOGICS, under the leadership of CEO Richard W. Lee, held a groundbreaking ceremony for its inaugural plant at the Songdo Bio Campus in Incheon International...

3 jui 2024
On June 29, the "Gather Great Wisdom to Shape the Future of Intelligent Manufacturing?Special Exhibition on Design Intelligence and High Quality Development", hosted by the China Academy of Art (CAA), opened at the National Museum of China in...

3 jui 2024
Intermap Technologies ("Intermap" or the "Company"), a global leader in 3D geospatial products and intelligence solutions, announces a new financing. The Company is offering up to a maximum of 4,300,000 Class "A" common shares of the Company...

3 jui 2024
"The Classic Quotes by Xi Jinping," a multilingual TV show produced by China Media Group, aired in Kazakhstan on Tuesday after Chinese...

3 jui 2024
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for hematological malignancies, announced today that on July 2, 2024, in relation to...



News published on and distributed by: